Cited by 497Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Cells and Metastasis

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Yauch, Robert L., Januario, Thomas, Eberhard, David A., Cavet, Guy, Zhu, Wenjing, Fu, Ling, Pham, Thinh Q., Soriano, Robert, Stinson, Jeremy, Seshagiri, Somasekar, Modrusan, Zora, Lin, Chin-Yu, O'Neill, Vincent, Amler, Lukas C.·2005·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-05-1492

Open this paper in CoChat — free account

Abstract

Significant improvements in the outcome of non-small cell lung carcinoma (NSCLC) have been reported in patients treated with the epidermal growth factor receptor (EGFR) inhibitor, erlotinib. To discover biomarkers for the enrichment of patients who might benefit from treatment, a pharmacogenomic approach was used to identify gene signatures that may predict erlotinib activity using in vitro model systems. Erlotinib sensitivity in a panel of 42 NSCLC cell lines was determined by EGFR-mediated proliferative potential, EGFR mutations, and/or EGFR gene amplification, thus supporting an underlying biological mechanism of receptor activation. A strong multigene signature indicative of an epithelial to mesenchymal transition (EMT) was identified as a determinant of insensitivity to erlotinib through both supervised and unsupervised gene expression approaches. This observation was further supported by expression analysis of classic EMT marker proteins, including E-cadherin and vimentin. To investigate the clinical relevance of these findings, we examined expression of the epithelial marker E-cadherin by immunohistochemistry on primary tumor samples from subjects enrolled in a randomized NSCLC clinical trial in which erlotinib in combination with chemotherapy previously failed to show clinical activity. The majority (75%) of the 87 subjects tested showed strong E-cadherin staining and exhibited a significantly longer time to progression (hazard ratio, 0.37; log rank P=0.0028) and a nonsignificant trend toward longer survival with erlotinib plus chemotherapy treatment versus chemotherapy alone. These data support a potential role for EMT as a determinant of EGFR activity in NSCLC tumor cells and E-cadherin expression as a novel biomarker predicting clinical activity of the EGFR inhibitor erlotinib in NSCLC patients.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-1492

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Show all 45 references

Sorted by citations

Items 401–497 of 497

[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].
Liu, H., Wang, M., Hu, K., Xu, Y., Ma, M., Zhong, W., Zhao, J., Li, L., & Wang, H. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.10.07 · Cited by 9
Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
Fu, W., Li, G., Lei, C., Qian, K., Zhang, S., Zhao, J., & Hu, S. (2023) · Theranostics · doi:10.7150/thno.82144 · Cited by 8
A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines
Wang, K., Shrestha, R., Wyatt, A. W., Reddy, A., Lehár, J., Wang, Y., Lapuk, A. V., & Collins, C. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103050 · Cited by 8
The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.
Voon, P. J., Cho, B. C., Yeo, W.-L., & Soo, R. A. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.02.03.6 · Cited by 8
Predicting drug sensitivity of cancer cells based on DNA methylation levels
Miranda, S., Baião, F., Maçaira, P., Fleck, J. L., & Piccolo, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0238757 · Cited by 9
Differentiated Epithelial- and Mesenchymal-Like Phenotypes in Subcutaneous Mouse Xenografts Using Diffusion Weighted-Magnetic Resonance Imaging
Chen, Y., Pan, H., Tseng, H., Chu, H., Hung, Y., Yen, Y., & Chou, C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121943 · Cited by 8
Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Kani, K., Faça, V. M., Hughes, L. D., Zhang, W., Fang, Q., Shahbaba, B., Luethy, R., Erde, J., Schmidt, J., Pitteri, S. J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0852 · Cited by 7
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Ware, K. E., Gilja, S., Xu, S., Shetler, S., Jolly, M. K., Wang, X., DeWitt, S. B., Hish, A. J., Jordan, S., Eward, W. C., et al. (2017) · Journal of Visualized Experiments · doi:10.3791/55520 · Cited by 7
Chemoresistance of Lung Cancer Cells: 2D and 3D In Vitro Models for Anticancer Drug Screening
Kaushik, V., Yakisich, J. S., Kulkarni, Y., Azad, N., & Iyer, A. K. V. (2018) · InTech eBooks · doi:10.5772/intechopen.78946 · Cited by 7
p70S6K Promotes Acquired Resistance of Erlotinib Through Induction of Epithelial-Mesenchymal Transition in Non-Small Cell Lung Carcinoma
Li, M., Chen, H., Sun, T., Ma, Z., Chen, X., Wu, D., Huang, W., & Wang, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s249695 · Cited by 6
E‐Cadherin Facilitates Protein Kinase D1 Activation and Subcellular Localization
Li, Z., Zhang, C., Chen, L., Li, G., Qu, L., Balaji, K. C., & Du, C. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25382 · Cited by 6
Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells
Duchemin-Pelletier, E., Baulard, M., Spreux, E., Orhant‐Prioux, M., Burute, M., Mograbi, B., Guyon, L., Théry, M., Cochet, C., & Filhol, O. (2017) · Cancers · doi:10.3390/cancers9090114 · Cited by 6
Molecular Characterization of Pancreatic Cancer Cell Lines
McConkey, D. J., Choi, W., Fournier, K. F., Marquis, L., Ramachandran, V., & Arumugam, T. (2009) · Springer eBooks · doi:10.1007/978-0-387-77498-5_19 · Cited by 6
Tumor Cell Plasticity in Cancer: Signaling Pathways and Pharmaceutical Interventions
Sun, S., Sun, Y., Lan, L., Luan, S., Zhou, J. R., Deng, J., Yuan, Y., & Wu, Z. (2025) · MedComm · doi:10.1002/mco2.70541 · Cited by 7
Cell-matrix adhesion characterization using multiple shear stress zones in single stepwise microchannel
Kim, M.-J., Doh, I., Bae, G.-Y., Cha, H., & Cho, Y.-H. (2014) · Applied Physics Letters · doi:10.1063/1.4892666 · Cited by 5
Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy
Zhuo, L., Guo, M., Zhang, S., Wu, J., Wang, M., Shen, Y., Peng, X., Wang, Z., Jiang, W., & Huang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116090 · Cited by 5
Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis
McConkey, D. J., & Choi, W. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_14 · Cited by 5
Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies
Eyzaguirre, A., Buck, E. A., Iwata, K. K., Haley, J. D., & Miglarese, M. R. (2008) · Targeted Oncology · doi:10.1007/s11523-008-0093-6 · Cited by 5
Molecular Basis of Lung Carcinogenesis
Fong, K. M., Larsen, J. E., Wright, C. M., Sriram, K. B., Davidson, M. R., Daniels, M. G., Sekido, Y., Bowman, R., Yang, I. A., & Minna, J. D. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_28 · Cited by 5
Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?
Arriola, E., Taus, Á., & Casadevall, D. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i4.45 · Cited by 4
Mechanisms of Cetuximab Resistance and How to Overcome It
Pauw, I. D., Boeckx, C., & Wouters, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-63234-2_3 · Cited by 4
Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
Afşar, Ç. U., Şahin, B., Günaldı, M., Bağır, E. K., Gümürdülü, D., Burgut, R., Erkişi, M. K., Kara, İ. O., Paydaş, S., Karaca, F., et al. (2015) · PubMed Central · Cited by 4
Impact of EMT in stage�IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
Villalobos, M., Czapiewski, P., Reinmuth, N., Fischer, J. X. F. R., Andreas, S., Kortsik, C., Serke, M. H., Wolf, M., Neuser, P., Reuß, A., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10153 · Cited by 4
Molecular Genetics of Lung and Pleural Neoplasms
Cagle, P. T., Jagirdar, J. S., & Popper, H. (2008) · Springer eBooks · doi:10.1007/978-0-387-72114-9_2 · Cited by 4
Inflammation and Lung Cancer: The Role of Epithelial–Mesenchymal Transition
Walser, T. C., Park, S. J., Yanagawa, J., & Dubinett, S. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2724-1_2 · Cited by 4
[Research progress on resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
Li, Y., & Song, L. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.02.08 · Cited by 3
MicroRNA-21 inhibitor potentiates anti-tumor effect of radiation therapy in vitro and in vivo
Cho, B. J., Kim, H. H., Lee, D., Choi, E. J., Hwang, Y. H., Chun, S. H., & Kim, I. A. (2014) · Tumor Microenvironment and Therapy · doi:10.2478/tumor-2014-0001 · Cited by 3
Cancer Stem Cells and Chemoresistance: Strategies to Overcome Therapeutic Resistance
Thomas, M. L., Coyle, K. M., Sultan, M., & Marcato, P. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_17 · Cited by 4
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB
Iwata, K. K., Beard, S. E., & Haley, J. D. (2007) · Elsevier eBooks · doi:10.1016/b978-012369393-8/50010-9 · Cited by 3
Clinical impact of studying epithelial–mesenchymal plasticity in pluripotent stem cells
Kovačic, B., Rosner, M., Schipany, K., Ionce, L., & Hengstschläger, M. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12415 · Cited by 3
[Epithelial-mesenchymal transition and tumor drug resistance].
Zhang, L., Wu, Z., & Zhou, Q. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.01.10 · Cited by 3
Expression of receptors tyrosine kinase c-kit and EGF-R in colorectal adenocarcinomas: is there a relationship with epithelial–mesenchymal transition during tumor progression?
Peparini, N., Caronna, R., Tellan, G., & Chirletti, P. (2009) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-009-0513-9 · Cited by 3
Drug Resistance in Cancer
Upadhyay, S. K., Rai, R. C., Gehtori, R., Paliwal, A., Gautam, P., & Joshi, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_20 · Cited by 4
Vitamin D and Lung Cancer
Shaurova, T., Seshadri, M., & Hershberger, P. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809963-6.00101-2 · Cited by 3
Connection between epithelial-mesenchymal transition and cancer stem cells and the potential therapeutic strategies
Xu, J., Geng, J., Ma, J., Lu, Y., Ma, F., Qin, Y., & Huang, B. (2025) · Human Gene · doi:10.1016/j.humgen.2025.201524 · Cited by 2
Mass Spectrometry and Pharmacological Approaches to Measuring Cooption and Reciprocal Activation of Receptor Tyrosine Kinases
Linzer, J. T., Phelps, Z., Vummidi, S., Lee, B. Y. E., Coant, N., & Haley, J. D. (2023) · Proteomes · doi:10.3390/proteomes11020020 · Cited by 2
Cancer Stem Cells in Lung Cancer: Roots of Drug Resistance and Targets for Novel Therapeutic Strategies
Gardelli, C., Sozzi, G., Roz, L., & Bertolini, G. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-16624-3_3 · Cited by 2
Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!
Easwaran, H., & Baylin, S. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0157 · Cited by 2
Matching Patients with Drugs: Triumphs and Challenges
Waring, P. M. (2006) · Personalized Medicine · doi:10.2217/17410541.3.3.335 · Cited by 2
Molecular Pathology of Lung Cancer
Corvalán, A. H., & Wistuba, I. I. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-524-8_1 · Cited by 2
Apoptosis Signaling Pathways in Pancreatic Cancer Pathogenesis
McConkey, D. J. (2009) · Springer eBooks · doi:10.1007/978-0-387-77498-5_14 · Cited by 2
Targeted Therapy in Non-Small Cell Lung Cancer
Stewart, D. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-424-1_7 · Cited by 2
Epidermal Growth Factor Receptor Mutation and Chemosensitivity
Matsubara, D., & Niki, T. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318245a058 · Cited by 2
Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies
Khoury, R., Raffoul, C., Hanna, C., Saleh, K., Shayya, A., Nahouli, M., & Ghanem, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125197 · Cited by 2
Mechanisms of disease: epithelial-mesenchymal transition and back again: does cellular plasticity fuel neoplastic progression?
Bissell, M. J., Turley, E. A., Veiseh, M., & Radisky, D. C. (2008) · University of North Texas Digital Library (University of North Texas) · Cited by 1
Assessment of erlotinib in chemoresponse assay.
Rice, S. D., Bush, J. E., & Brower, S. L. (2009) · PubMed · Cited by 1
Importance and Detection of Epithelial-to-Mesenchymal Transition (EMT) Phenotype in CTCs
Po, J. W., Lynch, D. T., SOUZA, P. D., & Becker, T. M. (2016) · InTech eBooks · doi:10.5772/64342 · Cited by 1
Resistance to EGFR Targeting Treatments in Colorectal Cancer
Pucci, M., & Lauriola, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00018-1 · Cited by 1
Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis
McConkey, D. J., & Choi, W. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_14-2 · Cited by 1
Non-small cell lung cancer map and analysis: exploring interconnected oncogenic signal integrators
Gottumukkala, S. B., & Palanisamy, A. (2025) · Mammalian Genome · doi:10.1007/s00335-025-10110-6 · Cited by 2
Targeting Signaling Pathways in Cancer Therapy
Berz, D., McCormack, E. M., Mega, A. E., & Wanebo, H. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_27 · Cited by 1
[Methodology of Establishing and Identifying NCI-H2228/Crizotinib-resistant Cell Lines In Vitro].
Wu, D., Jin, G.-H., Zhao, D., Zhang, Y., Zhao, J., & Yu, H. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.06.02 · Cited by 1
The Response of Cancer Cell Populations to Therapies
Lindsay, D., Garvey, C. M., Mumenthaler, S. M., & Foo, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804310-3.00010-7 · Cited by 1
Plasticité phénotypique et thérapies ciblées dans les cancers bronchiques non à petites cellules
Silva, J. D., Dalstein, V., Polette, M., & Nawrocki‐Raby, B. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.03.004 · Cited by 1
The intersection of EGFR and the Ras signaling pathway
Wislez, M., & Kurie, J. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_7 · Cited by 1
Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non‐Small Cell Lung Cancer
Massarelli, E. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch27 · Cited by 1
The role of E-cadherin in colon cancer drug resistance.
Murray, L. J. (2010) · Enlighten: Theses (The University of Glasgow) · Cited by 1
EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer
Eberhard, D. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_20 · Cited by 1
Self-citation
Identifiying oncogenic drivers in NSCLC cells harboring EGFR kinase domain mutation with resistance to EGFR TKI and mesenchymal phenotype
Gao, Y. (2014)
Cellular sensitivity to EGF receptor inhibitors
Thomson, S., Haley, J. D., & Yauch, R. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_22
Self-citation
Discovery of Predictive Biomarkers for Anticancer Drugs
Neve, R. M., Belmont, L. D., Bourgon, R., Evangelista, M., Huang, X., Schmidt, M., Yauch, R. L., & Settleman, J. E. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch02
Self-citation
Hedgehog signaling: A potential therapeutic target for non-small cell lung cancer
Maitah, M. Y. (2011) · Human Biology
Escape from Tumor Cell Dormancy
Griffith, L. G., & Wells, A. H. (2011) · doi:10.21236/ada555804
CANCELLED EMT and back again: does cellular plasticity fuel neoplasticprogressi on?
Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2007) · University of North Texas Digital Library (University of North Texas)
THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY
Balko, J. M. (2009) · UKnowledge (University of Kentucky)
Epithelial-to-Mesenchymal Transition and Cellular Membrane Receptors in Ovarian Cancer: Moving Forward in the Era of Molecularly Targeted Therapy
Martin, L. P., Perkins, J. J., & Schilder, R. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7216-3_8
Isolation of Cancer Stem Cells Showing Drug Resistance in the Human Epithelia Ovarian Cancer
Dong, Z., & Lai, D. (2013) · Stem cells and cancer stem cells · doi:10.1007/978-94-007-7329-5_9
Gene Expression Signatures –Ex Vivo/In VitroApproaches for Signature Development and Validation
Suresh, P. K., Ranganathan, K., Balasundaram, S., & Rajan, G. (2007) · International Journal of Human Genetics · doi:10.1080/09723757.2007.11885989
Loss of EGFR expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition
木村, 依. (2015) · Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University)
Utilizing combinations of molecular targeted agents to sensitize tumor cells to EGFR inhibitors
Buck, E. A., Eyzaguirre, A., & Iwata, K. K. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_23
r adiogenomic analysis Demonstrates associations
Yamamoto, S., Huang, D., Du, L., Korn, R. L., Jamshidi, N., Burnette, B., & Kuo, M. D. (2016)
Roles for transforming growth factor-α and transforming growth factor-ß in colorectal cancer
Coffey, R. J., & Beauchamp, R. D. (2006) · Current Colorectal Cancer Reports · doi:10.1007/s11888-006-0005-z
Mechanism of Resistance to Targeted Molecular Therapy
Seike, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_13
Targeting Neuropilin-1 in Prostate Cancer Bone Metastasis
Wu, D. (2010) · Defense Technical Information Center (DTIC) · doi:10.21236/ada538180
Immunomodulation and Vaccination with RHDV VLP
Donaldson, B. (2017) · Otago University Research Archive (University of Otago)
Dual Epidermal Growth Factor Inhibition and Multi Targeted Epigenetic Therapy (MTET)
Nezami, M. A., & Hager, S. (2018) · Journal of Cancer Therapy · doi:10.4236/jct.2018.911072
Drug development using pancreatic and lung organoid models
Choi, M., DeCelie, M. B., & Haley, J. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00014-3
New Approaches for the Treatment of Triple Negative Breast Cancer
Sulaiman, A. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-23348
Overcoming the drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancer cell lines
Liu, Z. (2018) · ThinkTech (Texas Tech University)
Investigation of the Role of CpG Methylation in Epithelial Mesenchymal Transition Master Genes in a Chemoresistant Ovarian Cancer Cell linePreprint
Alghamian, Y., Soukkarieh, C., Abbady, A. Q., & Murad, H. (2021) · Research Square · doi:10.21203/rs.3.rs-579729/v1
EGFR/Notch antagonists enhance the response to inhibitors of the PI3K-Akt pathway by decreasing tumor-initiating cell frequency
Li, T. X., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00010-9
Role of epithelial to mesenchymal transition in the resistant mechanism of EGFR-TKIs
Adachi, Y., & Ebi, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00005-x
EMT-Activating Transcription Factor Slug is Involved in the Phenotypic Change as Well as Drug Sensitivity in Adriamycin- Resistant MCF-7 Cells
Kim, S. H., Yu, M. R., & Jung, Y. (2023) · Drug Targets and Therapeutics · doi:10.58502/dtt.23.0005
Vitamin D in the management of lung cancer
Shaurova, T., Calkins, H., Seshadri, M., Johnson, C. S., & Hershberger, P. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91338-6.00040-9
BMP4-driven morphogenetic reprogramming sustains EGFR-TKI resistance via SOX2 suppression and EMT activation
Chen, A., Xie, D.-J., Jhu, Y., Lin, Y.-J., Wu, D.-Y., Yan, S.-L., Chou, Y., & Ko, J. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119281
Interleukine-15 et tumeurs du rein : implication de la cytokine dans la différenciation des cellules souches du cancer
Azzi, S. (2011) · theses.fr (ABES) · doi:10.70675/89e89d4dz7edez430ezb99cz3f5bdfd957b7
Implication du gène FHIT dans la régulation de l'invasion tumorale.
Joannes, A. (2011) · doi:10.70675/baf51a00z1556z4fa0z951ez19205dd3295f
Implication de Nanos-3 dans l’invasion tumorale broncho-pulmonaire
Grelet, S. (2014) · theses.fr (ABES) · doi:10.70675/9e0956d3z4c48z4e5dza8b1z287297610fb0
Contrôle de la progression tumorale broncho-pulmonaire par FHIT : Implication du récepteur HER2
Jouida, A. (2017) · theses.fr (ABES) · doi:10.70675/d7d69aafzfaebz4f24z855dz70ea0b9a846e
Implication de la matrice extracellulaire tumorale dans la transition phénotypique et la résistance aux thérapies ciblées du mélanome
Jouira, R. B. (2017) · theses.fr (ABES) · doi:10.70675/5c92bb26zb567z4576z822az745587210a70
Relation entre HER2 et FHIT dans la progression tumorale des cancers broncho-pulmonaires
silva, J. D. (2020) · doi:10.70675/89780163z0152z4453z8b8bzbf4db1a78e82
Rôle du facteur de transcription ZEB1 dans la progression et chimiorésistance du cholangiocarcinome
Lobe, C. (2019) · doi:10.70675/d2b2baa8zcc7bz47baz80d8z8ed50f0ad82e
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancerPreprint
Gini, B., Gui, P., Wu, W., Kerr, D. L., Tan, L., Barbosa, D., Olivas, V., Allegakoen, P., Gomez, C., Halliday, P. R., et al. (2026) · eLife · doi:10.7554/elife.111526.1
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancerPreprint
Gini, B., Gui, P., Wu, W., Kerr, D. L., Tan, L., Barbosa, D., Olivas, V., Allegakoen, P., Gomez, C., Halliday, P. R., et al. (2026) · eLife · doi:10.7554/elife.111526
BindingDB Entry 50015704: Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q2jq1508
BindingDB Entry 50009846: 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
BindingDB (2021) · UC San Diego · doi:10.7270/q2n301fs
BindingDB Entry 50021678: Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy.
BindingDB (2025) · UC San Diego · doi:10.7270/q2tq6676

Authors: Yauch, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., Pham, T. Q., Soriano, R., Stinson, J., Seshagiri, S., Modrusan, Z., Lin, C.-Y., O'Neill, V., & Amler, L. C.
Affiliations: Genentech (US)
5BioOncology, Genentech, Inc., South San Francisco, California
ORCID: Yauch, Robert L.
Fu, Ling
Seshagiri, Somasekar
Modrusan, Zora
Lin, Chin-Yu
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2005-12-15
Volume: 11
Issue: 24
Pages: 8686-8698
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-05-1492
OpenAlex: W2111599976
Cited by: 495
References: 45
Citations by year: 2026: 4 · 2025: 6 · 2023: 12 · 2022: 7 · 2021: 15 · 2020: 15 · 2019: 15 · 2018: 21 · 2017: 41 · 2016: 29 · 2015: 27 · 2014: 35 · 2013: 50 · 2012: 36
FWCI: 21.12
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Food and Drug Administration
Division of Materials Research
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: erlotinib, non-small cell lung cancer, epithelial-mesenchymal transition, E-cadherin, EGFR inhibitors, predictive biomarkers, pharmacogenomics, EGFR mutation, EGFR amplification, vimentin, time to progression, combination chemotherapy
MeSH terms: Erlotinib Hydrochloride, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Epithelium, Gene Amplification, Humans, Immunohistochemistry, Lung Neoplasms, Mesoderm, Mutation, Pharmacogenetics, Phenotype, Quinazolines, Biomarkers, Tumor, Vimentin, Cadherins, Treatment Outcome, Drug Resistance, Neoplasm, Oligonucleotide Array Sequence Analysis, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Genes, Neoplasm, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks